ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
Sep 22, 2026
DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC
Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence
DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.
The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.
Why this award matters
NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.
"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."
Patrick Smale, Co-founder and Chief Executive Officer
"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."
Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator
"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."
Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member
The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.
Important regulatory context
ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.
NIH funding acknowledgment
Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Media contact
Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761
Photos: (Click photo to enlarge)
Source: ClearSight Therapeutics, Inc.
Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source
Press release distribution by PRLog
More News
Maldives Pins Growth on GCC Connectivity, Halal Tourism, and Regional Investment
The island nation is ramping up its focus on the GCC market, bolstering regional air links and exploring halal tourism initiatives as part of its post-recovery strategy The post Maldives Pins Growth on GCC Connectivity, Halal Tourism, and Regional Investment appeared first on Business Traveller.
Chase Plans $70 Million Sapphire Lounge in Seattle
Chase is targeting 16,000 square feet at Seattle-Tacoma for a Sapphire Lounge, turning an abandoned public-lounge project into a lucrative private lease beside Delta’s growing premium complex. The post Chase Plans $70 Million Sapphire Lounge in Seattle appeared first on Business Traveller.
Non-Americans Are Sharing The Dumb, Dumb, Dumbbbbbest Things US Tourists Have Said To Them, And As An American, Embarrased Is An Understatement
"Look, that’s the moon! Do you have that in Ireland?" View Entire Post ›
Meet Paige Price, who is divorcing Malcolm in the Middle star Frankie Muniz
Actor Frankie Muniz, best known for playing the titular character in the hit sitcom Malcolm in the Middle, seems to be going through a rough patch. The 40-year-old, who is also a professional stock car racing driver, recently shared on Instagram that the last few weeks of his life have been “a nightmare [he’s] praying to wake up from”. Describing the situation as “hitting rock bottom”, the New Jersey native remains hopeful, writing, “In five years I believe I’ll look back at this exact low point...
Im DUSconference Plus am Düsseldorf Airport hebt Business ab
Ankommen, treffen, durchstarten: DUSconference plus ist die MICE Location direkt im Terminal des Düsseldorf Airport – gut erreichbar, flexibel planbar und mit einzigartigem Blick aufs Vorfeld. The post Im DUSconference Plus am Düsseldorf Airport hebt Business ab appeared first on Business Traveller.
Arbeiten im Ausland: Das bedeuten veränderte Mobilitätskosten für Expats und globale Teams
New York und London bleiben zwar teuer, doch Währungsschwankungen können die Kosten zusätzlich steigern oder dämpfen. So sind Städte wie Tokio für internationale Arbeitnehmer derzeit erschwinglicher, aber Sydney teurer. The post Arbeiten im Ausland: Das bedeuten veränderte Mobilitätskosten für Expats und globale Teams appeared first on Business Traveller.
Travel Around England And We'll Guess Your Favorite Beatle
Who is Abbey Road? View Entire Post ›
How Mid-Autumn Festival lanterns are traditionally made and an artisan defending the craft
While mass-produced Mid-Autumn Festival lanterns of every size, shape and style can be bought with a single click these days, a dedicated few in Hong Kong are defying the fast consumerism trend by keeping the objects’ traditional craftsmanship alive. Among them is Hong Kong fashion designer and lantern artisan Wan Wong, 52, who spends hours every year crafting traditional bamboo, wire and cellophane lanterns by hand. Lanterns remain a cherished centrepiece of the Mid-Autumn Festival, a Southeast...
Meet Sienna Miller’s daughter, Marlowe Sturridge, who attended the premiere of War
Sienna Miller’s 14-year-old daughter, Marlowe Sturridge, recently made a rare public appearance, joining her mother on the red carpet for the world premiere of Miller’s forthcoming television series War – a co-production of HBO and Sky – in London on September 16. Stepping out in contrasting styles, Miller wore a black feathered Dilara Findikoglu gown, while Marlowe took a relaxed approach in a graphic yellow baby tee and a black silk midi skirt. She finished the ensemble with Mary Jane flats...
A rainbow of iMac G3s? This 'old tech' party in L.A. is a balm for our isolated times
Welcome to Dead Internet Theory, a Y2K-era event that celebrates a time when social media meant AOL Instant Messenger and when tech evoked excitement rather than dread.
This major California river has gotten too warm for its salmon
The Sacramento River has gotten too warm for salmon eggs. Environmental advocates blame the Trump administration for taking too much water out of Shasta Lake.
How to break the negative habit of 'toxic multitasking'?
PRESS REVIEW – Tuesday, September 22: The Moscow Times talks about mobilisation rumours scaring anti-war activists in Russia. Next: The New York Times interviews South Korea's President Lee Jae Myung. Also: why is multitasking bad for the brain and the nervous system? Finally: this year's Fat Bear contest is starting in Alaska. Who's going to be the chonkiest chonk?
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.